ArticleJournal of Cancer2018
Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin
Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Exploring enterovirus pathogenesis and cancer therapy potential through reverse genetics.Biosafety and health · 2025Review
- Current status and research progress of oncolytic virus.Pharmaceutical science advances · 2024Review
- New Treatment Horizons in Uveal and Cutaneous Melanoma.Life (Basel, Switzerland) · 2023Review
- Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?Cancer cell international · 2022Review
- Article
- Cytolytic Properties and Genome Analysis of RigvirViruses · 2022Article
- Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors.Frontiers in cellular and infection microbiology · 2022Review
- 4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period.Toxicology reports · 2021Article
- Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus RigvirClinical case reports · 2020Article
- Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.BMC research notes · 2020Article
- Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems.Frontiers in cell and developmental biology · 2020Review
- Article
- Developing Picornaviruses for Cancer Therapy.Cancers · 2019Review
- Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.